- Home
- TXRH vs INSM Comparison
TXRH vs INSM Comparison
Compare TXRH & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXRH
- INSM
- Stock Information
- Founded
- TXRH 1993
- INSM 1988
- Country
- TXRH United States
- INSM United States
- Employees
- TXRH N/A
- INSM N/A
- Industry
- TXRH Restaurants
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- TXRH Consumer Discretionary
- INSM Health Care
- Exchange
- TXRH Nasdaq
- INSM Nasdaq
- Market Cap
- TXRH 12.2B
- INSM 14.3B
- IPO Year
- TXRH 2004
- INSM 2000
- Fundamental
- Price
- TXRH $168.38
- INSM $75.27
- Analyst Decision
- TXRH Buy
- INSM Strong Buy
- Analyst Count
- TXRH 24
- INSM 16
- Target Price
- TXRH $191.52
- INSM $94.64
- AVG Volume (30 Days)
- TXRH 1.5M
- INSM 2.0M
- Earning Date
- TXRH 05-01-2025
- INSM 02-20-2025
- Dividend Yield
- TXRH 1.55%
- INSM N/A
- EPS Growth
- TXRH 42.51
- INSM N/A
- EPS
- TXRH 6.47
- INSM N/A
- Revenue
- TXRH $5,373,332,000.00
- INSM $363,707,000.00
- Revenue This Year
- TXRH $10.79
- INSM $30.31
- Revenue Next Year
- TXRH $8.80
- INSM $118.39
- P/E Ratio
- TXRH $27.11
- INSM N/A
- Revenue Growth
- TXRH 16.01
- INSM 19.17
- 52 Week Low
- TXRH $146.75
- INSM $21.92
- 52 Week High
- TXRH $206.04
- INSM $84.91
- Technical
- Relative Strength Index (RSI)
- TXRH 40.50
- INSM 42.29
- Support Level
- TXRH $172.04
- INSM $71.57
- Resistance Level
- TXRH $183.57
- INSM $76.31
- Average True Range (ATR)
- TXRH 5.93
- INSM 3.15
- MACD
- TXRH -0.36
- INSM -0.78
- Stochastic Oscillator
- TXRH 18.72
- INSM 21.78
About TXRH Texas Roadhouse Inc.
Texas Roadhouse Inc is a restaurant company operating predominately in the casual dining segment. The company's operating segment includes Texas Roadhouse; Bubba's 33 and others. It generates maximum revenue from the Texas Roadhouse segment.
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.